Advancing personalized medicine requires close collaboration across stakeholders

by University of Eastern Finland

edited by Lisa Lock, reviewed by Andrew Zinin

Lisa Lock

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

The GIST Add as preferred source

The development of personalized medicine depends on collaboration among multiple stakeholders, who must navigate uncertainty while shaping expectations of future value. A recent study from the University of Eastern Finland published in Innovation examines how companies take part in this process and what kinds of challenges and opportunities emerge.

The study is based on 23 interviews with key actors in Finland, including companies, public-sector organizations and academic stakeholders. The findings show that shared understandings of the future are built through ongoing dialogue, in which stakeholders interpret and anticipate developments in the field.

Three main ways of framing the future of personalized medicine were identified. First, stakeholders assess potential benefits, such as improved health outcomes and cost savings. Second, they seek to combine resources and expertise to create value. Third, they form expectations about how the emerging field will develop and what kinds of opportunities it may offer.

At the same time, collaboration presents challenges. Company participation in early-stage innovation may be limited by differing interests, slow processes and a lack of shared understanding among stakeholders.

"Developing personalized medicine requires continuous dialogue between stakeholders. The key challenge is aligning different goals and perspectives," says Postdoctoral Researcher Ida Parkkinen from the University of Eastern Finland.

The study provides new insights into how future value is constructed in complex collaborative environments. The findings are relevant to both research and policymaking related to health care innovation.

More information

Ida Parkkinen et al, Business venture sensemaking on the future value of personalised medicine: healthcare innovation in a multistakeholder setting, Innovation (2026). DOI: 10.1080/14479338.2026.2689396

Provided by University of Eastern Finland Who's behind this story?

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Advancing personalized medicine requires close collaboration across stakeholders (2026, July 1) retrieved 1 July 2026 from https://medicalxpress.com/news/2026-07-advancing-personalized-medicine-requires-collaboration.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.